Literature DB >> 30718247

Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.

Gideon Stitt1,2, Jennifer Morris2, Lindsay Schmees2, Joseph Angelo3, Ayse Akcan Arikan3,4.   

Abstract

This retrospective study included pediatric intensive care unit patients receiving continuous veno-venous hemodiafiltration (CVVHDF) being treated with cefepime. The free drug concentration above one time the MIC (fT>1×MIC) and four times a presumed MIC (fT>4×MIC) of 8 μg/ml were calculated. Four patients received doses ranging from 48 to 64 mg/kg of body weight every 6 to 12 h. Three patients achieved 100% fT>1×MIC, with the fourth patient achieving 98% fT>1×MIC. Therapeutic drug monitoring should be considered for critically ill patients receiving cefepime on CVVHDF.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  intensive care units; pediatrics; pharmacodynamics; pharmacokinetics; renal replacement therapy

Mesh:

Substances:

Year:  2019        PMID: 30718247      PMCID: PMC6437530          DOI: 10.1128/AAC.02006-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Renal Replacement Therapy in the Critically Ill Child.

Authors:  Claire A Westrope; Sarah Fleming; Melpo Kapetanstrataki; Roger C Parslow; Kevin P Morris
Journal:  Pediatr Crit Care Med       Date:  2018-03       Impact factor: 3.624

2.  Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.

Authors:  Samuel L Aitken; Jerry Altshuler; David J Guervil; Elizabeth B Hirsch; Luis L Ostrosky-Zeichner; Charles D Ericsson; Vincent H Tam
Journal:  Int J Antimicrob Agents       Date:  2015-01-19       Impact factor: 5.283

3.  Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.

Authors:  B Allaouchiche; D Breilh; H Jaumain; B Gaillard; S Renard; M C Saux
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.

Authors:  Jason A Roberts; Marta Ulldemolins; Michael S Roberts; Brett McWhinney; Jacobus Ungerer; David L Paterson; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2010-08-03       Impact factor: 5.283

5.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

6.  Defining pediatric sepsis by different criteria: discrepancies in populations and implications for clinical practice.

Authors:  Scott L Weiss; Brandon Parker; Maria E Bullock; Sheila Swartz; Carolynn Price; Mark S Wainwright; Denise M Goodman
Journal:  Pediatr Crit Care Med       Date:  2012-07       Impact factor: 3.624

7.  Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.

Authors:  Arantxazu Isla; Alicia Rodríguez Gascón; Javier Maynar; Alazne Arzuaga; Darío Toral; José Luis Pedraz
Journal:  Clin Ther       Date:  2005-05       Impact factor: 3.393

Review 8.  Principles of antibacterial dosing in continuous renal replacement therapy.

Authors:  Gordon Choi; Charles D Gomersall; Qi Tian; Gavin M Joynt; Ross Freebairn; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2009-07       Impact factor: 7.598

9.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

Authors:  Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-03-04       Impact factor: 5.283

10.  Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.

Authors:  Lucie Seyler; Frédéric Cotton; Fabio Silvio Taccone; Daniel De Backer; Pascale Macours; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2011-06-06       Impact factor: 9.097

View more
  5 in total

1.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

2.  A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients.

Authors:  Taylor A Imburgia; Michelle L Kussin
Journal:  J Pediatr Pharmacol Ther       Date:  2022-03-21

3.  Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence.

Authors:  Gideon Stitt; Samuel Dubinsky; Andrea Edginton; Yuan-Shung V Huang; Athena F Zuppa; Kevin Watt; Kevin Downes
Journal:  Front Pediatr       Date:  2022-05-12       Impact factor: 3.569

4.  Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.

Authors:  Chiara Minotti; Elisa Barbieri; Denis Doni; Cristina Impieri; Carlo Giaquinto; Daniele Donà
Journal:  Front Pediatr       Date:  2022-04-26       Impact factor: 3.569

5.  Dosing Recommendations for Pediatric Patients With Renal Impairment.

Authors:  Amer Al-Khouja; Kyunghun Park; Daijha J C Anderson; Caitlyn Young; Jian Wang; Shiew Mei Huang; Mona Khurana; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2020-06-15       Impact factor: 3.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.